Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Hypoxia enhances the therapeutic potential of superparamagnetic iron oxide-labeled adipose-derived stem cells for myocardial infarction.

Wang J., Xiang B., Deng JX., Lin HY., Freed DH., Arora RC.

Animal Study on Cardiovascular Disease, published in J Huazhong Univ Sci Technolog Med Sci (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Huazhong Univ Sci Technolog Med Sci (2017)
Country
China
Reported sample size
—
Source database
PubMed
PMID
28786062
DOI
10.1007/s11596-017-1766-0
Citations
15

Abstract (original English)

Adipose-derived stem cells (ASCs) induce therapeutic angiogenesis due to pro-angiogenic cytokines secretion. Superparamagnetic iron oxide (SPIO) nanoparticles are critical for magnetic resonance (MR) tracking of implanted cells. Hypoxia is a powerful stimulus for angiogenic activity of ASCs. In this study, we investigated whether therapeutic potency could be enhanced by implantation of hypoxia-preconditioned SPIO-labeled ASCs ( SPIO ASCs) into the infarcted myocardium. ASCs and SPIO ASCs were cultured under 2% O 2 (hypoxia) or 95% air (normoxia). Cells were intramyocardially injected into the infarcted myocardium after 48-h culture. We found that hypoxia culture increased the mRNA expression of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) in ASCs and SPIO ASCs. The VEGF protein in the conditioned medium was significantly higher in hypoxic ASCs and SPIO ASCs than in normoxic ASCs and SPIO ASCs. The capillary density and left ventricular contractile function in the infarcted myocardium were significantly higher 4 weeks after implantation with hypoxic ASCs and SPIO ASCs than with normoxic ASCs and SPIO ASCs. Improvement in the capillary density and left ventricle function didn't differ between hypoxic ASCs-transplanted rats and hypoxic SPIO ASCs-transplanted rats. Hypoxic culture enhanced the angiogenic efficiency of ASCs. It was conclude

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsCapillariesCell HypoxiaCells, CulturedHypoxia-Inducible Factor 1, alpha SubunitMagnetite NanoparticlesMaleMyocardial ContractionMyocardial Infarction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research